Prelude Therapeutics Incorporated (PRLD) Cash Flow: Operating & Free Cash Flow

Prelude Therapeutics Incorporated Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Prelude Therapeutics Incorporated (PRLD) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	-99.50	-127.17	-121.83	-115.44	-111.69	-56.93	-27.57	-14.68
Depreciation & Amortization	1.34	1.77	1.17	1.32	0.92	0.54	0.38	0.15
Stock Based Compensation	11.91	21.35	25.62	25.14	20.93	5.58	0.85	0.18
Change in Working Capital	28.41	4.22	-10.48	0.93	3.63	4.62	0.67	1.38
Change in Accounts Payable	-3.92	3.31	-2.27	-0.35	3.90	1.16	0.55	0.72
Change in Other Working Capital	32.33	1.72	1.94	-5.55	-2.74	3.46	0.12	0.66
Other Operating Activities	1.53	-3.05	1.94	4.31	2.69	0.01	0.01	0.02
Net Cash from Operating Activities	-56.30	-102.89	-107.06	-83.73	-83.53	-46.18	-25.67	-12.95
Investing Activities
Capital Expenditures	-0.07	-0.76	-3.51	-3.02	-2.32	-0.62	-0.78	-0.53
Purchases of Investments	-100.87	-52.69	-221.63	-119.22	-261.48	0.00	0.00	0.00
Sales/Maturities of Investments	154.39	143.65	190.50	203.93	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	53.46	90.19	-34.65	81.69	-263.80	-0.62	-0.78	-0.53
Financing Activities
Debt Repayment	-0.21	-0.40	0.00	0.00	0.00	-0.26	-0.12	0.00
Common Stock Issued	25.04	0.44	135.73	0.82	165.20	166.73	0.00	17.94
Common Stock Repurchased	0.00	-0.05	-0.02	0.00	0.00	0.00	0.00	0.00
Other Financing Activities	-0.02	-0.11	-0.02	0.82	-0.30	-0.01	29.85	17.94
Net Cash from Financing Activities	24.82	-0.12	136.40	0.82	164.90	246.23	29.73	17.94
Summary
Net Change in Cash	21.97	-12.82	-5.31	-1.22	-182.44	199.43	3.28	4.45
Cash at Beginning of Period	16.52	29.34	34.65	35.87	218.31	18.88	15.60	11.14
Cash at End of Period	38.49	16.52	29.34	34.65	35.87	218.31	18.88	15.60
Free Cash Flow	-56.37	-103.65	-110.58	-86.75	-85.85	-46.80	-26.45	-13.48

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Prelude Therapeutics Incorporated Cash Flow

What is Prelude Therapeutics Incorporated's free cash flow?

Prelude Therapeutics Incorporated had negative free cash flow of $56.37M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$56.30M minus $67.00K of capital expenditures.

How much does Prelude Therapeutics Incorporated spend on capital expenditures?

Prelude Therapeutics Incorporated spent $67.00K on capital expenditures in fiscal 2025, compared with $764.00K a year earlier.

Does Prelude Therapeutics Incorporated pay dividends or buy back shares?

Prelude Therapeutics Incorporated's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition